Aydın AYTEKİN, Fatih KARAKAŞ, M. Bekir HACIOĞLU, Mustafa ALTINBAŞ, Süleyman ŞAHİN

Nüks Larinks Kanseri Nedeniyle Fistül Cerrahisi Yapılan Hastada Yara İyileşmesinde Bozulma ve Setuksimab'ın Rolü: Olgu Sunumu

Epidermal büyüme faktörü (EGFR), yara iyileşmesinde re-epitelizasyonu indükleyerek önemli bir role sahiptir.Tümör yayılımında EGFR ekspresyonu ve onun büyümeyi indükleyen süreçlerinde değişiklik meydana gelerekmetastaz gelişimine ve kontrolsüz hücre büyümesine neden olur. EGFRnin bu rollerinden dolayı anti-EGFR tedaviler geliştirilmiştir ve bu tedavilerin klinik çalışmalarla değişik tümör tiplerinde etkili olduğu kanıtlanmıştır.Anti- EGFR tedavi için geliştirilen ilaçlardan biri olan setuksimab, skuamöz hücreli baş-boyun kanserlerinde rekürren veya metastatik hastalıkta kullanım onayı almıştır. Mevcut datalar ışığında anti-EGFR ilaçların bu konudakipotansiyel etkisi tam olarak gösterilememiştir. Biz burada 57 yaşında larinks kanseri nedeniyle setuksimab alan birhastada meydana gelen yara iyileşmesi bozukluğunu sizinle paylaşmak istedik.

Role of Cetuximab in Wound Healing Impairment in a Patient Operated for Fistula Tract Due to Recurrent Larynx Cancer- A Case Report

Epidermal growth factor receptor (EGFR) has an important role in wound healing by promoting re-epithelialization.In tumorigenesis, EGFR expression and its downstream causes metastasis and uncontrolled cell growth by makingchanges in promoting processes. Because of its role in these processes, anti-EGFR therapies have been developedand have been proven effective in clinical trials for a variety of tumor types. One of these events is cetuximab whichis approved in treatment of recurrent or metastatic squamous cell head and neck cancer. Up to day with current datas,negative effects of anti-EGFR treatment over re-epithelialization is uncertain. Herein, we presented a wound healingimpairment due to cetuximab in a 57- year-old male patient treated for fistula tract caused by recurrent larynx cancer.

PDF

___

1. Barrientos S, Stojadinovic O, Golinko MS, et al. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008; 16(5):585–601.
2. Martin P. Wound healing--aiming for perfect skin regeneration. Science. 1997; 276(5309):75–81.
3. Tokumaru S, Higashiyama S, Endo T, et al. Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing. J Cell Biol. 2000; 151(2):209–220.
4. Ando Y, Jensen PJ. Epidermal growth factor and insulin-like growth factor I enhance keratinocyte migration. J Invest Dermatol. 1993; 100(5):633–639.
5. Toffoli G, De Mattia E, Cecchin E, et al. Pharmacology of epidermal growth factor inhibitors. Int J Biol Markers. 2007; 22(1 Suppl 4):S24–39.
6. Hanna N, Lilenbaum R, Ansari R, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol. 2006; 24(33):5253–5258.
7. Krempien R, Muenter MW, Huber PE, et al. Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PAR C: study protocol (ISRCTN56652283). BMC Cancer. 2005; 5:131.
8. Kawamoto T, Sato JD, Le A, et al. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A. 1983; 80(5):1337–1341.
9. Tibbs MK. Wound healing following radiation therapy: a review. Radiother Oncol. 1997; 42(2):99–106.
10. Tokarek R, Bernstein EF, Sullivan F, et al. Effect of therapeutic radiation on wound healing. Clin Dermatol. 1994; 12(1):57–70.
11. N.R. Dean, L. Sweeny, P.M. Harari, J.A. Bonner, V. Jones, L.Clemons, H. Geye, and E.L. Rosenthal, Wound healing following combined radiation and cetuximab therapy in ahead and neck cancer patients. J Wound Care. 2011 April ; 20(4): 166–170.
12. Yeh S, Fine HA, Smith JA. Corneal verticillata after dual antiepidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. Cornea. 2009 Jul;28(6):699-702.
13. Potthoff K, Habl G, Bruckner T, et al. Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial. BMC Cancer. 2014 Apr 17;14:270
14. Pinta F, Ponzetti A, Spadi R. et al. Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2014 Mar;13(1):62-7